Loading stock…

Haemonetics Corporation (HAE) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Haemonetics Corporation

HAEMarket cap $4.63BPrice $101.7

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Equipment

Makes blood management systems and devices used in surgeries, plasma collection, and hospital transfusions worldwide. Its plasma-collection tech is so dominant that most donation centers rely on Haemonetics equipment to keep the blood supply chain running safely.

In Bastion Portfolios?

52W Return+102%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+5%5

Revenue Forecast

Rev CAGR (1y)+6%5

Rev CAGR (3y)+6%5

Rev CAGR (5y)+14%8

Earnings Forecast

EPS Growth Y+1+161%10

EPS Growth Y+2+9%6

EPS Growth Y+3+10%7

Quality

Margins

EBIT Margin19%7

Net Income Margin7%4

Free Cash Flow Margin22%8

Debt

Net Debt/EBITDA2.63

Efficiency

ROE11%5

ROA4%5

Earnings Stability88

GEAR+STRONG69

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)194

P/E Ratio (Forward 3y)164

P/BV5.53

EV Multiples

EV/EBITDA Fwd125

EV/EBIT Fwd156

Yield

Free Cash Flow Yield6.3%7

Dividend Yieldna–

Momentum

Short term

1 month return-1%7

3 month return+38%10

YTD return+27%8

Mid term

Price vs 52wHigh92%9

1 year return+100%10

Long term

3 year return+13%3

5 year return+51%6

Risk Shield

Price Risk

Beta0.48

Volatility46%4

Free Cash Flow

Free Cash Flow Margin22%8

Free Cash Flow Yield6.3%7

Quality

ROCE13%7

Earnings Stability88

Net Debt/EBITDA2.63

02Growth

Is it actually growing, and how fast?

HAEHaemonetics

Revenue FY26$1.3B

GROWTH RATING↗

AVERAGE59 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+5%5

Revenue, next 1Y+6%5

Revenue, next 3Y, CAGR+6%5

Revenue, next 5Y, CAGR+14%8

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+161%10

EPS growth, FY28E+9%6

EPS growth, FY29E+10%7

GROWTH ASSESSMENT

STRENGTHS

The runway holds up: revenue is set to grow 14%/yr over five years.8/10

Earnings are set to grow in step with sales (EPS about 10%/yr vs revenue 6%/yr).

WATCH

A mid-pack grower, ahead of 59% of companies worldwide.

Revenue is set to grow 6%/yr over the next 3 years, a little ahead of the market.6/10

Revenue grew 5%/yr over the last 3 years and is set to keep growing around 6%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG84 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-1%7

3-month return+38%10

YTD return+27%8

MID & LONG-TERM▾SCORE

% of 52-week high92%9

1-year return+100%10

3-year return+13%3

5-year return+51%6

MOMENTUM ASSESSMENT

STRENGTHS

It's up 100% over the past year, now 8% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (-1%), over three months (+38%) and so far this year (+27%).

WATCH

Average long-term results. Multi-year returns are middling (+13% over three years and +51% over five), roughly average for the market.

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on Haemonetics Corporation. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

HAEHaemonetics

Revenue FY26$1.3B

GROWTH RATING↗

AVERAGE59 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+5%5

Revenue, next 1Y+6%5

Revenue, next 3Y, CAGR+6%5

Revenue, next 5Y, CAGR+14%8

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+161%10

EPS growth, FY28E+9%6

EPS growth, FY29E+10%7

GROWTH ASSESSMENT

STRENGTHS

The runway holds up: revenue is set to grow 14%/yr over five years.8/10

Earnings are set to grow in step with sales (EPS about 10%/yr vs revenue 6%/yr).

WATCH

A mid-pack grower, ahead of 59% of companies worldwide.

Revenue is set to grow 6%/yr over the next 3 years, a little ahead of the market.6/10

Revenue grew 5%/yr over the last 3 years and is set to keep growing around 6%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG84 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-1%7

3-month return+38%10

YTD return+27%8

MID & LONG-TERM▾SCORE

% of 52-week high92%9

1-year return+100%10

3-year return+13%3

5-year return+51%6

MOMENTUM ASSESSMENT

STRENGTHS

It's up 100% over the past year, now 8% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (-1%), over three months (+38%) and so far this year (+27%).

WATCH

Average long-term results. Multi-year returns are middling (+13% over three years and +51% over five), roughly average for the market.

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on Haemonetics Corporation. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community